| Tammy Stanfield, PHARMD | |
|
215 Airport Rd, Hot Springs, AR 71913-4060 | |
| (501) 623-2650 | |
| Not Available |
| Full Name | Tammy Stanfield |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 215 Airport Rd, Hot Springs, Arkansas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134767569 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | PD09136 (Arkansas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Tammy Stanfield, PHARMD 215 Airport Rd, Hot Springs, AR 71913-4060 Ph: (501) 623-2650 | Tammy Stanfield, PHARMD 215 Airport Rd, Hot Springs, AR 71913-4060 Ph: (501) 623-2650 |
News Archive
Scientists at The New York Stem Cell Foundation Research Institute successfully designed a revolutionary, high-throughput, robotic platform that automates and standardizes the process of transforming patient samples into stem cells.
A post hoc analysis of the PETACC-8 trial has revealed an interaction between microsatellite instability and BRAF and KRAS mutation status when determining the prognosis of patients with resected stage III colon adenocarcinoma.
Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including muscle, bone, fat, red blood cells and the vasculature, today announced it received FDA Fast Track designation for ACE-031 for the treatment of Duchenne Muscular Dystrophy (DMD), a fatal neuromuscular disease in which patients suffer from the progressive loss of muscle mass and strength. ACE-031 is an investigational protein therapeutic being developed to increase muscle mass and strength.
Mersana Therapeutics, a platform-based cancer therapeutics company, today announced that it has initiated a Phase 1 clinical trial to study the safety and pharmacokinetics of XMT-1107 in patients with refractory advanced solid tumors. XMT-1107 is a novel anti-angiogenic fumagillin analog that employs Mersana's Fleximer platform. Mersana's XMT-1001, a conjugate of Fleximer and camptothecin, is currently completing a Phase 1 study.
Trendlines Labs (a unit of the Trendlines Group) recently signed an agreement for collaboration with Roper St. Francis Healthcare.
› Verified 9 days ago
Corey Lee Williams, D.PH. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3631 Central Ave, Hot Springs, AR 71913 Phone: 501-762-7748 | |
Domonique Deshea Wadley, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 998 Shady Grove Rd Ste 1h, Hot Springs, AR 71901 Phone: 501-262-5400 Fax: 501-262-5404 | |
Justin Blake Sperry, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3631 Central Ave, Hot Springs, AR 71913 Phone: 501-623-4377 | |
Kenneth Ray Wedsted, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1800 Airport Rd, Hot Springs, AR 71913 Phone: 501-760-2089 Fax: 501-760-2435 | |
Pamela Leanne Anthony, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3631 Central Ave, Hot Springs, AR 71913 Phone: 501-623-4377 | |
James Robert Carter, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1404 Albert Pike Rd, Hot Springs, AR 71913 Phone: 501-318-1248 | |
Karol Sue Farnell, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 105 Reserve St, 105 Reserve, Hot Springs, AR 71901 Phone: 501-624-4411 Fax: 501-624-0019 |